LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$5.1M | -$3.6M | -$5.1M | -$6.3M | -$6.7M |
| Operating expenses | $5.1M | $3.6M | $5.1M | $6.3M | $6.7M |
| Cash from operations | -$3.1M | -$3.2M | -$4.3M | -$4.6M | -$4.1M |
| Total assets | $12.7M | $1.1M | $4.3M | $5.6M | $5.1M |
| Total liabilities | $1.8M | $318,284 | — | — | — |
Shares outstanding 12.4M · Free float 70.3%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.